

Sigma Receptor

Antagonists

NE-100

Selective σ_1 antagonist (IC₅₀'s: σ_1 = 1.5nM, σ_2 = 85nM).¹

Product No: 10-4200 5 mg 25 mg

BD1047 dihydrobromide

Potent and selective σ_1 antagonist (IC₅₀'s: σ_1 = 0.93nM, σ_2 = 47nM).² Also inhibits the β -adrenoreceptor (IC₅₀ = 145 nM).²

Product No: 10-4210 5 mg 25 mg

BD1063 dihydrochloride

Potent and selective σ_1 antagonist (IC₅₀'s: σ_1 = 9nM, σ_2 = 449nM).²

Product No: 10-4211 5 mg 25 mg

S1RA

S1RA (E-52862) is a potent and selective σ_1 antagonist with weak binding at σ_2 (IC₅₀'s: σ_1 = 17nM, σ_2 = 9300nM).³

Product No: 10-4201 5 mg 25 mg

Agonists

Cutamesine (SA4503)

Cutamesine (SA4503) is an agonist of the σ receptor with selectivity for the σ_1 subtype (IC₅₀'s: σ_1 = 17.4 nM, σ_2 = 1784nM).⁴

Product No: 10-4219 5 mg 25 mg

Siramesine

Siramesine (Lu 28-179) is a σ_2 selective agonist (IC₅₀'s: σ_1 = 17nM, σ_2 = 0.2nM).⁵

Product No: 10-4202 5 mg 25 mg

PRE084

PRE084 is an agonist of the σ receptor with selectivity for the σ_1 subtype (IC₅₀'s: σ_1 = 2.2nM, σ_2 = 13091nM).⁶

Product No: 10-4203 5 mg 25 mg

DTG

Non-selective high affinity ligand for the σ receptor (IC₅₀'s ~ 30nM).^{7,8}

Product No: 10-4204 100 mg 500 mg

PB28 dihydrochloride


Very potent high affinity (K_i = 5.3 nM¹, 0.34 nM²) σ_2 agonist. Selective for σ_2 over σ_1 (approx 30-40x).⁹

Product No: 10-4665 5 mg 25 mg


Pridopidine

Selective σ_1 agonist¹⁰ with neuroprotective and neurorestorative properties.

Product No: 10-4003 5 mg 25 mg



S1RA



Siramesine

References

1. Chaki *et al.* (1994), *Eur.J.Pharmacol.* **251** R1
2. Matsumoto *et al.* (1995), *Eur.J.Pharmacol* **280** 301
3. Romero *et al.* (2012), *Br.J.Pharmacol.* **166** 2289
4. Lever *et al.* (2006), *Synapse* **59** 350
5. Soby *et al.* (2002), *Neuropharmacology* **43** 95
6. Su *et al.* (1991), *J.Pharmacol.Exp.Ther.* **259** 543
7. Weber *et al.* (1986). *PNAS* **83** 8784
8. Scherz *et al.* (1990) *J.Med.Chem.* **33** 2421
9. Berardi *et al.* (2004) *J. Med. Chem.* **47** 2308
10. Naia *et al.* (2021) *Neurotherapeutics* **18** 1017